High frequency transcutaneous electrical nerve stimulation was reported to be beneficial in patients with angina. ' Accepted for publication 24 January 1989
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Patients and methods
PATIENTS
Eleven patients (two women and nine men aged 50-71 years (mean 61 years)) were chosen from among those visiting the outpatient clinic at the medical department, Ostra Hospital. All patients had severe angina (functional class III-IV New York Heart Association) despite their taking optimal antianginal medication. No patients had obstructive or restrictive pulmonary disease, intermittent claudication, valvar heart disease, or untreated hypertension. Eight patients had had a myocardial infarction more than six months before the study. All patients had chest pain and ST segment depression (0-1-0 7 mV) during a maximal symptom limited bicycle ergometer test. On scintigraphic examination, ischaemia ofthe anterior wall ofthe myocardium was seen in 10 patients when thallium was injected during exercise testing. All patients had been considered for bypass operation: four patients had been operated on but still had disabling angina pectoris, and one was waiting for operation. Four of these patients had three vessel disease, one had two vessel disease, and one had single vessel disease. heart rate. The pacing rate was increased by 10 beats/ minute every minute, continuing until the patient could not tolerate a further increase in pain. New measurements and blood samples were taken. Pacing was then stopped. After 25 minutes rest without pacing, transcutaneous electrical nerve stimulation treatment was started. Fifteen minutes later, new baseline measurements and blood samples were taken. After another five minutes the same pacing routine was repeated and repeat measurements were made at the same pacing rate as that at which angina had been produced during the previous control recording. Exactly five minutes before the repeat measurements a single dose of 50 mg naloxone or the equivalent amount of saline as placebo was given by infusion, double blind in random order. The pacing was not interrupted during infusion of naloxone or physiological saline. The pacing rate was then increased until the patient considered the chest pain to be as intense as it was during control registration before treatment with transcutaneous electrical nerve stimulation. New pressure recordings and blood samples were then taken (figure). If the patient did not experience chest pain, pacing was stopped at 170 beats/minute.
CALCULATIONS
Coronary vascular resistance (mm Hg/ml/min) was estimated as mean arterial blood pressure divided by coronary sinus blood flow. The myocardial oxygen consumption (ml/min) was calculated as the myocardial arteriovenous oxygen difference multiplied by coronary blood flow. The myocardial lactate extraction ratio (%) was expressed as 100 x (arterial lactate concentration -coronary sinus lactate concentration) divided by the arterial lactate concentration.
The myocardial arteriovenous difference for adrenaline reflects its extraction from the coronary circulation, because only the brain and the adrenal medulla can synthesise and release adrenaline.7 Thus adrenaline (A) uptake (nmol/min) equals the arteriovenous difference in adrenaline x coronary sinus blood flow. In addition to being extracted from the coronary circulation, noradrenaline is also released from sympathetic nerve endings and the myocardial arteriovenous difference in noradrenaline is thus the result of a combined uptake and release of the catecholamine and will be referred to as "noradrenaline overflow" (nmol/min), which equals the arteriovenous difference x coronary sinus blood flow. Adrenaline and noradrenaline share the same uptake mechanisms and the extraction ratio seems to be similar as well,7 so noradrenaline uptake (nmol/min) Mannheimer, Emanuelsson, Waagstein, Wilhelmsson can be estimated as: percentage adrenaline uptake x coronary sinus blood flow x noradrenaline arterial concentration. Net myocardial noradrenaline release can be calculated by assuming that the inflow of noradrenaline (coronary sinus blood flow x arterial noradrenaline concentration) + release -uptake = efflux ofnoradrenaline (coronary sinus blood flow x coronary sinus concentration)-that is noradrenaline release (nmol/min) equals coronary sinus blood flow x (coronary sinus -arterial noradrenaline concentration) + noradrenaline uptake.
Time to angina (seconds) was calculated as the time from the start of atrial pacing until pain and recovery time (seconds) as the time after the pacing was stopped until pain disappeared.
STATISTICAL METHODS
We used the difference between the correspoifding values at rest and during pacing to compare saline and naloxone and control and transcutaneous electrical nerve stimulation. Fisher's test for pair comparisons was applied to the differences.8 All tests were two tailed. Whether or not the differences should be used depends on the correlation coefficient between the baseline value and the current value. If the coefficient exceeds 0 50, it is better to use the difference. Excess of this limit was justified in this study. The results were analysed as follows (figure)- 
Discussion
The results of this study indicate that the positive effects of high frequency transcutaneous electrical nerve stimulation in angina induced by pacing-that is increased tolerance to pacing, improved lactate metabolism, and less anginal pain-are reproducible. None of these effects was reversed by naloxone.
Atrial pacing is considered to be a sufficiently reproducible method if the heart rate is quickly increased to the anginal value and a recovery period of at least 20 minutes is allowed between control and treatment sessions.9'0 The recovery period in the present study was Mannheimer, Emanuelsson, Waagstein, Wilhelmsson During transcutaneous electrical nerve stimulation and naloxone there was no significant increase oftime to angina compared with control. However, when the differences between time to angina during transcutaneous electrical nerve stimulation plus placebo and control were compared with the difference between transcutaneous electrical nerve stimulation plus naloxone and control there was no significant difference. But the presence ofa significant difference between transcutaneous electrical nerve stimulation and no stimulation for placebo treatment and the absence of such a difference for naloxone treatment or the converse must not be interpreted as a statistically significant difference between placebo and naloxone.
Opioids have been suggested as mediators of numerous physiological and pathophysiological processes and opiate receptors have been identified in many peripheral organs, including the adrenal medulla, sympathetic ganglia, and the heart.1' 12 The effects of transcutaneous electrical nerve stimulation have been suggested to be at least partly mediated by endogenous opioids. " Different frequencies of stimulation are assumed to activate different opioid systems. For example, in one investigation Woolf et al found that high frequency transcutaneous electrical nerve stimulation had an opioid-dependent antinociceptive effect in rats that was abolished by naloxone (1 mg/kg).'4 However, other studies showed that low frequency electrostimulation releases f endorphins, which can be blocked by naloxone, while high frequency stimulation, which was used in this study, may release met-enkephalin, which was not blocked by conventional doses of naloxone." 6 This may explain why naloxone did not block the effects of transcutaneous electrical nerve stimulation in this study, in which high frequency transcutaneous electrical nerve stimulation was used.
The single intravenous dose ofnaloxone needed to block the effects ofexogenously administered opioids is 0-4-0-8 mg. Cohen et al showed that systolic blood pressure and respiratory responses increased with the dose of naloxone in normal adults (0 3 mg/kg-4 mg/kg).'7 They concluded that the lower doses of naloxone previously used in human studies were not sufficient to block completely endogenous opioid systems. Thus despite the high dose ofnaloxone used in this study (0 7 mg/kg given as a single dose of 50 mg), it might still have been insufficient to block every type of opioid receptor. Naloxone is known to have high affinity for p receptors.'8 However, the drug only attenuated the response to a 3 agonist and was ineffective against the K agonist, ketazocine.'9 Dynorphin is a potent and selective ligand for K receptors.'" In a previous study an increase of dynorphin was found in two patients studied during Influence of naloxone on the effects of highfrequency transcutaneous electrical nerve stimulation 41 transcutaneous electrical nerve stimulation at the corresponding pacing rate.21 Thus if the effects of transcutaneous electrical nerve stimulation are mediated by met-enkephalin or dynorphin, the doses of naloxone used in this study might have been insufficient to block the a and K receptors. f Endorphin has high affinity for p receptors.' It therefore seems less likely that the antianginal effects of high frequency transcutaneous electrical nerve stimulation in pacing induced angina are mediated by f endorphin in view of the apparent lack of effect of naloxone in this study. However, it is possible that a more specific 3 or K antagonist blocked the effects of transcutaneous electrical nerve stimulation in the present study.
Evidence suggests that transcutaneous electrical nerve stimulation may influence autonomic systems mainly by suppressing sympathetic overactivity.' Evidence from several studies suggests that opioid peptides may act upon cardiovascular receptors."9 Enkephalin, dynorphin, and the 3 and K opioid receptors have all been shown in guinea pig hearts.' It has been suggested that opioid peptides may affect the local modulation of sympathetic cardiac neurotransmission. In general, the opioid systems seem to become active only during pathophysiological conditions such as stress, pain, and hypoxia and they seem to have an inhibitory or modulating influence.425 They are co-stored with catecholamines in sympathetic ganglia and the adrenal medulla and are believed to modify their release and inhibit sympathetic activity.' Transcutaneous electrical nerve stimulation was recently found to increase pacing tolerance, improve lactate metabolism, and reduce ST segment depression.27 These effects were thought to be caused by a decrease in left ventricular afterload, as reflected by a fall in systolic blood pressure secondary to reduced sympathetic activity; this mechanism accords with the fall in arterial concentrations of adrenaline and noradrenaline during transcutaneous electrical nerve stimulation in those who responded to transcutaneous electrical nerve stimulation. However, in this study, there were no changes in arterial catecholamine concentrations or systemic blood pressure during transcutaneous electrical nerve stimulation. Patient population, timing of blood sampling, and the method of analysing catecholamines were exactly the same in the two studies. There were no other methodological problems that could explain the different results obtained.
It is also possible that non-opioid mechanisms are important in mediating the effects of transcutaneous electrical nerve stimulation. For example parachlorophenylalanine, an inhibitor of serotonin synthesis, reduced the analgesic effect of high frequency electroacupuncture in mice whereas naloxone did not.' Conversely, naloxone completely reversed the effects of low frequency stimulation but parachlorophenylalanine did not have any effect. There are serotoninergic neurones from the medulla to the spinal dorsal horns. This descending pathway activates inhibitory enkephalinergic interneurones which in turn block the pain signal at the segmental level.' High frequency electrostimulation, which is strictly segmental, might activate this inhibitory serotoninergic pathway.
The positive effects of high frequency transcutaneous electrical nerve stimulation in angina induced by pacing-increased tolerance to pacing, improved lactate metabolism, and less angina-were reproducible and not reversed by single intravenous doses of 50 mg naloxone. The effects of transcutaneous electrical nerve stimulation therefore seem not to be mediated by fi endorphin, but the treatment might activate more short-acting a or K agonists such as met-enkephalin or dynorphin because naloxone has low affinity with these receptors. It is also possible that non-opioid mechanisms are important.
